{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:02:39Z","timestamp":1782802959380,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clml.2024.02.006","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T13:40:54Z","timestamp":1707918054000},"page":"e227-e234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-1067","authenticated-orcid":false,"given":"Hira","family":"Mian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6701-1714","authenticated-orcid":false,"given":"Hsien","family":"Seow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1033-0882","authenticated-orcid":false,"given":"Gregory R.","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Gayowsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9817-8011","authenticated-orcid":false,"given":"Ronan","family":"Foley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaris","family":"Balistky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Ebraheem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Cipkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyra","family":"Sapru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4297-8042","authenticated-orcid":false,"given":"Samer Al","family":"Hadidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alissa","family":"Visram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2024.02.006_bib0001","series-title":"Lyon, France: IARC Press; 2008. WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Swerdlow","year":"2008"},{"issue":"2","key":"10.1016\/j.clml.2024.02.006_bib0002","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/bjh.18185","article-title":"How I treat triple-class refractory multiple myeloma","volume":"198","author":"Costa","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.02.006_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1027385","article-title":"Immunotherapy for the treatment of multiple myeloma","volume":"13","author":"Boussi","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.clml.2024.02.006_bib0004","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/s41375-021-01433-9","article-title":"Outcomes of triple class (proteasome inhibitor, IMiDs and monoclonal antibody) refractory patients with multiple myeloma","volume":"36","author":"Zanwar","year":"2022","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2024.02.006_bib0005","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41375-021-01471-3","article-title":"Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies","volume":"36","author":"Bal","year":"2022","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.clml.2024.02.006_bib0006","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","article-title":"LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and\/or refractory multiple myeloma","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"issue":"10","key":"10.1016\/j.clml.2024.02.006_bib0007","doi-asserted-by":"crossref","first-page":"e341","DOI":"10.1016\/j.clml.2023.07.006","article-title":"Real-world health care services utilization associated with the management of patients with relapsed and refractory multiple myeloma in spain: the CharisMMa study","volume":"23","author":"Ocio","year":"2023","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"31","key":"10.1016\/j.clml.2024.02.006_bib0008","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.2217\/fon-2023-0021","article-title":"Real-world treatment patterns, healthcare resource use and disease burden in patients with multiple myeloma in Europe","volume":"19","author":"Mart\u00ednez-Lopez","year":"2023","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.clml.2024.02.006_bib0009","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1681\/ASN.2017080882","article-title":"Causes of death after a hospitalization with AKI","volume":"29","author":"Silver","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.clml.2024.02.006_bib0010","unstructured":"Cancer Care Ontario (Drug Formulary). https:\/\/www.cancercareontario.ca\/en\/drugformulary\/regimens. Accessed November 30."},{"issue":"2","key":"10.1016\/j.clml.2024.02.006_bib0011","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/082585979100700202","article-title":"The edmonton symptom assessment system (ESAS): a simple method for the assessment of palliative care patients","volume":"7","author":"Bruera","year":"1991","journal-title":"J Palliat Care"},{"issue":"9","key":"10.1016\/j.clml.2024.02.006_bib0012","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1002\/(SICI)1097-0142(20000501)88:9<2164::AID-CNCR24>3.0.CO;2-5","article-title":"Validation of the edmonton symptom assessment scale","volume":"88","author":"Chang","year":"2000","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.clml.2024.02.006_bib0013","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/0269216307087659","article-title":"The edmonton symptom assessment system: a 15-year retrospective review of validation studies (1991\u20132006)","volume":"22","author":"Nekolaichuk","year":"2008","journal-title":"Palliat Med"},{"issue":"3","key":"10.1016\/j.clml.2024.02.006_bib0014","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jpainsymman.2016.10.370","article-title":"The edmonton symptom assessment system 25 years later: past, present, and future developments","volume":"53","author":"Hui","year":"2017","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.clml.2024.02.006_bib0015","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jpainsymman.2008.12.006","article-title":"Development, implementation, and process evaluation of a regional palliative care quality improvement project","volume":"38","author":"Dudgeon","year":"2009","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10.1016\/j.clml.2024.02.006_bib0016","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","article-title":"Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases","volume":"45","author":"Deyo","year":"1992","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.clml.2024.02.006_bib0017","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1001\/jamainternmed.2014.6300","article-title":"Geographic accessibility to clinical trials for advanced cancer in the United States","volume":"175","author":"Galsky","year":"2015","journal-title":"JAMA Intern. Med."},{"issue":"1","key":"10.1016\/j.clml.2024.02.006_bib0018","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.clml.2019.09.625","article-title":"Randomized clinical trial representativeness and outcomes in real-world patients: comparison of 6 hallmark randomized clinical trials of relapsed\/refractory multiple myeloma","volume":"20","author":"Chari","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2024.02.006_bib0019","unstructured":"Surveillance E, and End Results Program, National Cancer Institute (NCI), United States. https:\/\/seer.cancer.gov\/statfacts\/html\/mulmy.html. Accessed Nov 30, 2023."},{"issue":"1","key":"10.1016\/j.clml.2024.02.006_bib0020","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1186\/s12885-020-07503-y","article-title":"Frontline treatment patterns and attrition rates by subsequent lines of therapy in patients with newly diagnosed multiple myeloma","volume":"20","author":"Fonseca","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2024.02.006_bib0021","unstructured":"Canada's Drug and Health Technology Agency. Mutliple Myeloma Algorithm. https:\/\/www.cadth.ca\/multiple-myeloma. Accessed Nov 30."},{"issue":"3","key":"10.1016\/j.clml.2024.02.006_bib0022","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.3390\/curroncol29030132","article-title":"Sequential use of carfilzomib and pomalidomide in relapsed multiple myeloma: a report from the canadian myeloma research group (CMRG) database","volume":"29","author":"McCurdy","year":"2022","journal-title":"Current Oncology"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2024.02.006_bib0023","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-112138","article-title":"Development of thrombocytopenia and survival outcomes in newly diagnosed multiple myeloma","volume":"132","author":"Mellors","year":"2018","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.clml.2024.02.006_bib0024","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo","year":"2015","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.clml.2024.02.006_bib0025","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/OP.21.00032","article-title":"Immunotherapy in multiple myeloma\u2014time for a second major paradigm shift","volume":"17","author":"Mohan","year":"2021","journal-title":"JCO Oncology Practice"},{"issue":"4","key":"10.1016\/j.clml.2024.02.006_bib0026","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1111\/bjh.17898","article-title":"Clinical trial participation improves survival outcomes by increasing availability of new therapeutic agents in multiple myeloma","volume":"196","author":"Jung","year":"2022","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2024.02.006_bib0027","doi-asserted-by":"crossref","unstructured":"Nickolich MS, El-Jawahri A, Temel JS, LeBlanc TW. Discussing the evidence for upstream palliative care in improving outcomes in advanced cancer. Am Soci Clin Oncol:e534-e538. 10.1200\/edbk_159224.","DOI":"10.1200\/EDBK_159224"},{"issue":"5","key":"10.1016\/j.clml.2024.02.006_bib0028","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/ejh.13843","article-title":"Palliative care utilization, transfusion burden, and end-of-life care for patients with multiple myeloma","volume":"109","author":"McInturf","year":"2022","journal-title":"Eur J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2024.02.006_bib0029","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/bjh.18401","article-title":"Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario","volume":"199","author":"Mohyuddin","year":"2022","journal-title":"British J Haematol"},{"issue":"1","key":"10.1016\/j.clml.2024.02.006_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41408-021-00602-4","article-title":"Patient-reported outcome measures are associated with health care utilization in patients with transplant ineligible multiple myeloma: a population-based study","volume":"12","author":"Mian","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400065X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502400065X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T00:56:13Z","timestamp":1728953773000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502400065X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S215226502400065X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.006","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment Pattern, Healthcare Resource Utilization and Symptom Burden Among Patients with Triple Class Exposed Multiple Myeloma: A Population-Based Cohort Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2024.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}